NASDAQ:AVTE Aerovate Therapeutics (AVTE) Stock Price, News & Analysis $1.92 +0.02 (+1.05%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$1.86▼$1.9650-Day Range$1.61▼$2.0152-Week Range$1.25▼$32.42Volume114,080 shsAverage Volume524,716 shsMarket Capitalization$55.43 millionP/E RatioN/ADividend YieldN/APrice Target$2.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aerovate Therapeutics alerts: Email Address Aerovate Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.6% Upside$2.25 Price TargetShort InterestBearish5.93% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$375,450 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.74) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 starsMedical Sector470th out of 899 stocksPharmaceutical Preparations Industry216th out of 420 stocks 3.0 Analyst's Opinion Consensus RatingAerovate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAerovate Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aerovate Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.93% of the float of Aerovate Therapeutics has been sold short.Short Interest Ratio / Days to CoverAerovate Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aerovate Therapeutics has recently increased by 23.54%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerovate Therapeutics does not currently pay a dividend.Dividend GrowthAerovate Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVTE. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Aerovate Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for AVTE on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Aerovate Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerovate Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $375,450.00 in company stock.Percentage Held by Insiders24.90% of the stock of Aerovate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Aerovate Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aerovate Therapeutics are expected to grow in the coming year, from ($2.74) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerovate Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerovate Therapeutics is -0.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAerovate Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aerovate Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About Aerovate Therapeutics Stock (NASDAQ:AVTE)Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Read More AVTE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVTE Stock News HeadlinesSeptember 4, 2024 | americanbankingnews.comBrokerages Set Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Target Price at $2.25July 8, 2024 | globenewswire.comAerovate Therapeutics to Explore Strategic AlternativesSeptember 9, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.June 21, 2024 | globenewswire.comInvestigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLCJune 20, 2024 | globenewswire.comAerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law FirmJune 17, 2024 | globenewswire.comSHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & LevitonJune 17, 2024 | globenewswire.comAerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionJune 11, 2024 | seekingalpha.comAerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH MarketSeptember 9, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.May 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Aerovate Therapeutics (AVTE), Exact Sciences (EXAS)May 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: AbbVie (ABBV), Aerovate Therapeutics (AVTE)May 21, 2024 | globenewswire.comAerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceMay 14, 2024 | msn.comAerovate Therapeutics reports Q1 GAAP EPS of -$0.83May 13, 2024 | investorplace.comAVTE Stock Earnings: Aerovate Therapeutics Misses EPS for Q1 2024May 13, 2024 | globenewswire.comAerovate Therapeutics Announces First Quarter Financial Results and Business HighlightsApril 20, 2024 | investing.comAerovate Therapeutics exec sells shares worth over $153,000April 20, 2024 | investing.comAerovate Therapeutics CEO sells over $246k in company stockApril 4, 2024 | finance.yahoo.comAerovate Therapeutics Inc CEO Timothy Noyes Sells 10,000 SharesSee More Headlines Receive AVTE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerovate Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/09/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTE CUSIPN/A CIK1798749 Webaerovatetx.com Phone617-443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$2.25 High Stock Price Target$3.00 Low Stock Price Target$2.00 Potential Upside/Downside+18.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-83.65% Return on Assets-72.26% Debt Debt-to-Equity RatioN/A Current Ratio6.51 Quick Ratio6.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.96 per share Price / Book0.48Miscellaneous Outstanding Shares28,870,000Free Float21,645,000Market Cap$54.85 million OptionableOptionable Beta1.03 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Timothy P. Noyes M.B.A. (Age 62)CEO & Director Comp: $936.9kMr. George A. Eldridge (Age 61)CFO & Treasurer Comp: $658.6kMr. Timothy J. Pigot (Age 53)Chief Commercial Officer Comp: $584.6kDr. Benjamin T. Dake Ph.D. (Age 48)Founder, President, COO & Secretary Comp: $435.5kDr. Marinus Verwijs Ph.D. (Age 48)Chief Technical Officer Comp: $439.88kDr. Ralph W. Niven M.B.A. (Age 64)M.R, Ph.D., Pharm.S, Chief Scientific Officer Comp: $372.33kMr. Hunter Gillies M.D. (Age 58)Chief Medical Officer Comp: $512.74kMs. Donna DeaHead of Regulatory AffairsMs. Susan FischerExecutive Vice President of Development OperationsMr. Stephen K. YuSenior Vice President of QualityMore ExecutivesKey CompetitorsMagenta TherapeuticsNASDAQ:MGTALeap TherapeuticsNASDAQ:LPTXCytomX TherapeuticsNASDAQ:CTMXImmunicNASDAQ:IMUXProcaps GroupNASDAQ:PROCView All CompetitorsInsiders & InstitutionsDeerfield Management Company L.P. Series CBought 1,411,608 shares on 8/15/2024Ownership: 4.898%Affinity Asset Advisors LLCBought 200,000 shares on 8/15/2024Ownership: 0.694%Cubist Systematic Strategies LLCBought 31,894 shares on 8/14/2024Ownership: 0.111%XTX Topco LtdBought 21,143 shares on 8/12/2024Ownership: 0.073%Warberg Asset Management LLCBought 67,449 shares on 8/9/2024Ownership: 0.234%View All Insider TransactionsView All Institutional Transactions AVTE Stock Analysis - Frequently Asked Questions How have AVTE shares performed this year? Aerovate Therapeutics' stock was trading at $22.63 on January 1st, 2024. Since then, AVTE stock has decreased by 91.5% and is now trading at $1.93. View the best growth stocks for 2024 here. How were Aerovate Therapeutics' earnings last quarter? Aerovate Therapeutics, Inc. (NASDAQ:AVTE) posted its earnings results on Monday, August, 12th. The company reported ($0.86) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by $0.10. When did Aerovate Therapeutics IPO? Aerovate Therapeutics (AVTE) raised $100 million in an initial public offering on Wednesday, June 30th 2021. The company issued 7,150,000 shares at a price of $13.00-$15.00 per share. Who are Aerovate Therapeutics' major shareholders? Aerovate Therapeutics' top institutional shareholders include Atlas Venture Life Science Advisors LLC (6.24%), Deerfield Management Company L.P. Series C (4.90%), Affinity Asset Advisors LLC (0.69%) and SG Americas Securities LLC (0.62%). Insiders that own company stock include David S Grayzel, Hunter Gillies, George A Eldridge, Ralph Niven, Benjamin T Dake, Marinus Verwijs and Timothy P Noyes. View institutional ownership trends. How do I buy shares of Aerovate Therapeutics? Shares of AVTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AVTE) was last updated on 9/9/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredSell NVDA Now?Just weeks before last month’s selloff, Citadel – the most successful hedge fund in history – quietly sold 500...Chaikin Analytics | Sponsored‘Wheels Are Falling Off’ the U.S. Stock Market"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredCan Apple’s AI News Make You Rich?September 20th 2024: AI’s “iPhone Moment” Apple is making a major move on Friday, September 20th. And what ...Banyan Hill Publishing | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTE Stock Alerts